Dr. Jacqueline Nube

Position:Patent Scientist
Email:jacqueline.nube@spruson.com
Jacqueline Nube

Academic Qualification

QualificationInstitutionYear of Completion
Graduate Certificate in Intellectual Property Law National University of Singapore2016
Dr. rer. nat. (Biochemistry)Julius-Maximilians University Würzburg2013
Dipl.-Biol. (BSc/MSc equivalent)Julius-Maximilians University Würzburg2010

Industry Experience

PositionOrganisation/InstitutionDate of Tenure
Research ScientistGenelux Corporation, San Diego, USA2010 - 2013

Selected Patent Cooperation Treaty (PCT) Specifications

PCT Publication NumberTitle of Application
WO 2016/108758 Technique for formation and assembly of 3d cellular structures
WO 2016/130085Dermatopontin as a therapeutic for metabolic disorders
WO 2017/146653A simple one-step real-time molecular sensor for microrna detection
WO 2016/175708 Microchip-based elisa for rapid serodiagnosis of tuberculosis
WO 2017/048197 Use of niclosamide in the treatment of p53-deficient cells
WO 2017/078631 Chemical-inducible genome engineering technology
WO 2017/123161 Inhibition of intracellular growth of mycobacterium species and its applications (full spec; pct conversion; no claims)
WO 2017/160234 Generation of midbrain-specific organoids from human pluripotent stem cells
WO 2017/192102 Mitochondrial delivery of recombinant nucleic acids
WO 2017/217935 Consequences of a defective switch in cutaneous squamous cell carcinoma (scc)
WO 2017/209697Genetic alteration in antisense long non-coding rna as a biomarker for susceptibility to disease treatment
WO 2018/034620 Immunosuppressive composition for use in treating immunological disorders
WO 2018/056907 Novel target and methodology to inhibit skin inflammation and blunt skin cancer susceptibility
WO 2018/199849 Characteristic urine metabolites in spontaneous miscarriages
WO 2019/070204 Method for treating natural killer/t-cell lymphoma
WO 2019/143292 Method for differentiation of human pluripotent stem cell lines in suspension culture
WO 2019/164451 Cancer therapeutic targeting using mutant P53-specific siRNAs
Experience and Technical Background

Experienced in the following areas of patent practice:

  • Drafting
  • Local and Foreign Patent Prosecution
  • Patentability Advice
  • Extensions of Patent Term (Pharmaceuticals)
  • Patent Searches

Primary patent practice areas by technology:

  • Virology
  • Biochemistry
  • Cloning and Gene editing
  • Pharmaceutical Biology
  • Molecular Biology
  • Proteins
  • Cell Biology
  • Antibodies

Research/industry background:

A. General technical areas:

  • Virology
  • Protein (over-) expression and purification
  • Pharmacokinetics
  • Pharmacodynamics
  • Cancer mouse models
  • in vivo testing
  • blood-based analysis

B. Honours research:

  • “Experiments on the Expression of a DLD-fusion protein in Mammalian Cells” at the Institute for Clinical Biochemistry, Würzburg.
  • Identified methods for enabling and improving gene expression of the DLD fusion protein
  • Focus on gene editing, cloning and protein expression

C. PhD research:

  • Dissertation on “Comparative Analysis of Vaccinia Virus-Encoded Markers Reflecting Actual Viral Titres in Oncolytic Virotherapy”: Using viruses to treat cancer is a novel approach to an age-old disease. Oncolytic viruses are native or recombinant viruses that have the innate or enhanced capability to infect tumour cells, replicate within the tumour microenvironment and subsequently lyse those cells. Since imaging modalities offer little insight into viral replication deep within the body, and because oncolytic virotherapy is dependent on replication within the target tissue, the need for a monitoring system is evident. Pharmacokinetic analysis of this oncolytic agent was to give insight into the dynamics present in tumours during treatment. This, in turn, would give clinicians the opportunity to monitor the efficacy as early as possible after the onset of treatment, to observe treatment progression and possibly to gauge prognosis, without resorting to invasive procedures, e.g. biopsies.
  • Doctorate Scholarship program between the Julius-Maximilians University Würzburg and Genelux Corporation, San Diego.

D. Industry experience:

  • Post as a research scientist at Genelux Corporation, San Diego, working with the Vaccinia virus.

Would you like to join the Spruson & Ferguson team?


Work For Us

Contact our Expert Team

Contact Us